Lothian NHS Board

Waverley Court
4 East Market Street
Edinburgh
EH8 8BG

Telephone: 0131 536 9000
www.nhslothian.scot.nhs.uk

Date: 17/11/2026
Our Ref: 12075
Enquiries to loth.freedomofinfomation@nhs.scot

Dear

FREEDOM OF INFORMATION – CANCER TREATMENT

I write in response to your request for information in relation to cancer treatment in NHS Lothian.

Question:

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2026 and the end of September 2026, or latest 3-month period available?

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Patient treatment, July – September 2026, NHS Lothian	
Name of medicine	**Number patients treated**
1.1 Abemaciclib (Verzenios)	48
1.2 Alpelisib (Piqray)	0
1.3 Camizestrant (Etcamah)	0
1.4 Capivasertib (Truqap)	0
1.5 Elacestrant (Orserdu)	0
1.6 Elinzanetant (Lynkuet)	0
1.7 Fulvestrant (fulvestrant or Faslodex)	77
1.8 Inavolisib (Inaqovi)	0
1.9 Imlunestrant (Inluriyo)	≤5
1.10 Olaparib (Lynparza)	22
1.11 Palbociclib (Ibrance)	29
1.12 Ribociclib (Kisqali)	70
1.13 Talazoparib (Talzenna)	0
1.14 Vepdegestrant (Veppanu)	0

Question:

2. How many patients were treated in total, regardless of diagnosis, with the following products in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-months for which data are available?

Answer:

The information you have requested is detailed in the table below.

Patient treatment, July – September 2026, NHS Lothian	
Name of medicine	**Number patients treated**
2.1 Pertuzumab (Perjeta)	21
2.2 Pertuzumab with Trastuzumab (Phesgo)	92
2.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	87
2.4 Trastuzumab Deruxtecan (Enhertu)	35
2.5 Trastuzumab Emtansine (Kadcyla)	14
2.6 Tucatinib (Tukysa)	6
2.7 Neratinib (Nerlynx)	0

Question:

3. How many patients were treated specifically for breast cancer (*ICD-10 codes = C50*, D05)* in the 3 months between 1st July 2026 and the end of September 2026?

Answer:

The information you have requested is detailed in the table below.

Treatment for breast cancer, July – September 2026, NHS Lothian	
Breast Cancer	**Number patients treated**
3.1 Olaparib - All types of breast cancer	7
3.2 Talazoparib – All types of breast cancer	0
3.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) - All types of breast cancer	82
3.4 Trastuzumab Deruxtecan (Enhertu) - All types of breast cancer	34

Question:

4. How many patients received the following medicines with curative treatment intent in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period for which data are available?

Answer:

The information you have requested is detailed in the table below.

Curative treatment, July – September 2026, NHS Lothian	
Name of combination or monotherapy	**Number patients treated**
4.1 Abemaciclib (Verzenios)	33
4.2 Ribociclib (Kisqali)	17
4.3 Pertuzumab (Perjeta)	15
4.4 Pertuzumab with Trastuzumab (Phesgo)	56
4.5 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	53
4.6 Trastuzumab Emtansine (Kadcyla)	9

Question:

5. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period for which data are available?

Answer:

The information you have requested is detailed in the table below.

Neoadjuvant and adjuvant treatment, July – September 2026, NHS Lothian	
Products	**Total Neo-adj or adjuvant**
5.1 Olaparib (Lynparza)	14
5.2 Pertuzumab (Perjeta)	15
5.3 Pertuzumab with Trastuzumab (Phesgo)	56
5.4 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	53
5.5 Trastuzumab Emtansine (Kadcyla)	9

Question:

6. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period for which data are available? HER2+ve and HER2-low breast cancer.

Answer:

This information is not collected centrally. This is because our hospital electronic prescribing system does not link prescribing to this level of diagnosis. Information will be held in individual patient records, but in order to provide the information you request it would be necessary to review each patient record over the period you have specified,

requiring significant resources. Under section 12 of the Freedom of Information (Scotland) Act 2002, NHS Lothian is not required to respond to your request if the resources required to do so equate to more than £600 in cost.

Question:

7. How many patients were treated with the following medicines in combination in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period available?

Answer:

The information you have requested is detailed in the table below.

Patient treatment, July – September 2026, NHS Lothian	
Name of combination or monotherapy	**Number patients treated**
7.1 Pertuzumab + Trastuzumab (Phesgo) + Taxane (Docetaxel or Paclitaxel)	21
7.2 Pertuzumab (Perjeta) + Trastuzumab Deruxtecan (Enhertu)	0

Question:

8. How many submissions for funding were made to the Cancer Drugs Fund for trastuzumab deruxtecan (Enhertu) with the following BlueTeq codes in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period available?

TRAD1 “Trastuzumab Deruxtecan (Enhertu) for HER2+ve unresectable, locally advanced or metastatic breast cancer in patients who have received 2 or more anti-HER2 therapies and received trastuzumab emtansine (Kadcyla)”

TRAD2 “Trastuzumab Deruxtecan (Enhertu) for HER2+ve unresectable, locally advanced or metastatic breast cancer in patients who have received 1 or more anti-HER2 therapies and received trastuzumab emtansine (Kadcyla)”

TRAD3 “Trastuzumab Deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy”

Answer:

The BlueTeq codes are not used in NHS Scotland, so this is not applicable to us.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply

within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at https://www.foi.scot/appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: https://org.nhslothian.scot/FOI

Yours sincerely

ALISON MACDONALD
Executive Director of Nursing Midwifery and AHPs
Cc: Chief Executive